Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-21 02:01 UTC

BIOMED PULSE

Monday, September 21, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo has reached 61 health zones across six provinces and remains the largest Ebola outbreak ever recorded in DRC, with sustained cross-border transmission into Uganda still driving case counts upward. [1]

Overall mood: grave on outbreak containment; cautiously active on aging-related trial enrollment.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS (EBOLA) - DRC AND UGANDA

  • As of September 10, 2026, the Bundibugyo virus disease (BVD) outbreak has expanded to 61 affected health zones, adding Kayna in North Kivu as the latest, spanning six of DRC's 26 provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo. [1]
  • WHO designates this the largest Ebola outbreak ever reported in DRC and notes it is expanding faster than any previous Ebola outbreak in the country, with sustained transmission in health facilities and communities driving the surge. [2]
  • Cross-border transmission into Uganda remains active; the WHO Disease Outbreak News series (DON602 through DON617) documents cumulative confirmed cases growing from 515 on June 6 to well over 2,100 by mid-July, with case fatality among confirmed cases exceeding 30 percent. [3] [4] [5]
  • CDC mobilized its Emergency Operations Center for Ebola response on May 17, 2026 and expanded enhanced airport screening from Washington Dulles to Atlanta Hartsfield-Jackson for travelers arriving from affected regions. [6] [7] [8]

ANIMAL RABIES - UNITED STATES

  • CDC issued a statement on September 10, 2026, flagging a notable increase in animal rabies activity and associated human exposure events across the United States; no human rabies deaths were specified but public vigilance around animal bites was urged. [9]

ANTIMICROBIAL RESISTANCE - UNITED STATES

  • A CDC report released September 23, 2025 found a dramatic increase in a dangerous category of drug-resistant bacteria in U.S. healthcare settings, building on prior warnings about carbapenem-resistant and other extensively drug-resistant organisms. [10]
  • A separate extensively drug-resistant Salmonella outbreak linked to moringa powder capsules was reported in February 2026, with three hospitalizations and ongoing spread to 28 states as of late January 2026.

SALMONELLA - ONGOING U.S. OUTBREAKS

  • CDC is actively tracking multiple simultaneous Salmonella outbreaks: jalapeños (alert issued August 5, 2026), alfalfa sprouts co-infected with E. coli (alert August 21, 2026), and a continuing backyard poultry outbreak that had sickened over 150 people with more than a quarter of cases in children under five.

CYCLOSPORA - TACO BELL LETTUCE

  • Shredded iceberg lettuce served at Taco Bell locations in five states was confirmed as the source of a Cyclospora cayetanensis outbreak; 1,644 people were reported sick as of July 17, 2026, with the outbreak later expanding to four additional states.

CONGENITAL SYPHILIS - UNITED STATES

  • New CDC data released September 24, 2025 showed U.S. cases of syphilis in newborns increased for the 12th consecutive year in 2024, underscoring persistent gaps in prenatal screening and treatment.

🧬 LONGEVITY & AGING

UROLITHIN A AND GLUCOSE METABOLISM IN OLDER ADULTS

  • ClinicalTrials.gov lists an active randomized triple-masked controlled trial (NCT06274749) evaluating whether Urolithin A (UA) supplementation improves glucose metabolism and pancreatic beta-cell insulin secretion in healthy adults aged 55 and older, targeting a key mechanism by which aging raises type 2 diabetes risk.
  • Urolithin A is a gut-microbiome-derived metabolite of ellagitannins (found in pomegranates and walnuts) proposed to enhance mitophagy, the cellular recycling of damaged mitochondria, which declines with age.

DECISION-MAKING SUPPORT FOR AGING WITH MEMORY LOSS

  • The DECIDE: Dyads and Families trial (NCT05139290) is testing a culturally tailored decision-making support program for African American adult daughters acting as healthcare proxies for parents living with memory loss, addressing a documented disparity in dementia caregiving resources.

FUNCTIONAL REACH TEST IN ELDERLY FALL PREVENTION

  • A registered study (NCT05853406) aims to establish a Minimal Clinically Important Difference for the Functional Reach Test in elderly populations using both statistical and anchor-based methods, which would sharpen the clinical threshold for identifying fall-risk patients needing intervention.

💊 NEW CURES & APPROVALS

PIXCLARA (FLORETYROSINE F 18) - TELIX PHARMACEUTICALS US INC

  • openFDA records an original NDA approval (NDA218592) for PIXCLARA, whose active ingredient is Floretyrosine F 18, a fluorine-18 labeled amino acid radiotracer used in PET imaging, sponsored by Telix Pharmaceuticals US Inc.

DASATINIB - MSN LABORATORIES (GENERIC)

  • openFDA records an original ANDA approval (ANDA219579) for a generic formulation of Dasatinib by MSN Laboratories; Dasatinib is a BCR-ABL and Src-family kinase inhibitor used in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, and is also under active investigation as a senolytic agent in aging research.

EPINEPHRINE - ZYDUS PHARMACEUTICALS

  • openFDA records an original ANDA approval (ANDA219832) for an epinephrine formulation by Zydus Pharmaceuticals, expanding the generic supply of this critical emergency anaphylaxis and cardiac resuscitation drug.

COLISTIMETHATE SODIUM - SAGENT PHARMACEUTICALS (SUPPLEMENT)

  • openFDA records a supplemental ANDA action (ANDA201365) for Colistimethate Sodium by Sagent Pharmaceuticals Inc, a last-resort antibiotic active against carbapenem-resistant gram-negative pathogens including Acinetobacter baumannii and Pseudomonas aeruginosa, relevant given the CDC report of rising drug-resistant bacteria. [10]

🧪 CLINICAL TRIALS

NEOANTIGEN T CELL THERAPY FOR BLOOD CANCERS WITH TP53/RAS MUTATIONS

  • Trial NCT06904066, registered September 18, 2026, is testing autologous T cells transduced with retroviral vectors expressing patient-specific T cell receptors targeting neoepitopes arising from TP53 or RAS mutations in hematologic malignancies including leukemia; this approach attempts to exploit the very mutations that make cancers treatment-resistant.

ETAVOPIVAT IN PEDIATRIC SICKLE CELL DISEASE

  • Trial NCT06198712 is evaluating pharmacokinetics and safety of etavopivat, a pyruvate kinase R activator that improves red blood cell oxygen affinity and reduces sickling, in pediatric patients with sickle cell disease enrolled in a staggered age-descending manner.

ACUTE MYELOID LEUKEMIA - MYELOMATCH PLATFORM

  • The MyeloMATCH Phase II platform trial (NCT05554406), updated September 18, 2026, is comparing standard cytarabine plus daunorubicin against several experimental arms including liposomal daunorubicin-cytarabine, venetoclax combinations, and targeted agents in newly diagnosed high-risk AML patients.

HIV VACCINE BOOSTER - CD40.HIVRI.ENV (VRIPRO) PLUS HILTONOL

  • Trial NCT06665646 is enrolling 40 HIV-negative participants aged 18 to 60 who previously completed the HVTN 706 vaccine trial to receive three injections (weeks 0, 4, and 24) of the CD40-targeting HIV envelope immunogen VRIPRO adjuvanted with Poly-ICLC (Hiltonol), testing whether a targeted dendritic cell strategy can deepen durable HIV-specific immunity.

ULCERATIVE COLITIS - FIRST-LINE BIOLOGIC SELECTION RCT

  • The START trial (NCT07576452) is a randomized controlled trial evaluating the optimal first-line biologic sequence in ulcerative colitis patients, relevant to the growing population of IBD sufferers including older adults in whom chronic inflammation is a recognized accelerant of biological aging.

📢 PUBLIC HEALTH

LISTERIA - EXPANDED PREPARED FOODS OUTBREAK

  • CDC expanded its active Listeria monocytogenes outbreak alert on September 26, 2025 to include additional prepared meal products, reporting three new illnesses and one additional death; consumers were urged to check refrigerators and freezers for recalled items and discard them immediately.

DRUG OVERDOSE DEATHS DECLINING

  • CDC data from May 2025 showed a 27 percent decrease in drug overdose deaths in 2024, building on a 24 percent decline reported in February 2025, representing the largest two-year sustained drop in overdose mortality on record.

U.S.-WHO WITHDRAWAL COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026; WHO stated the decision makes both the U.S. and the world less safe and indicated the issue would be considered at the World Health Assembly.

WEST NILE VIRUS - EARLY SEASON RECORD CASES

  • CDC warned on July 1, 2026 of an early and unusually active West Nile virus season with record case counts, urging Americans to use EPA-registered insect repellents, wear long sleeves at dusk, and eliminate standing water around homes.

KINDERGARTEN VACCINATION RATES

  • CDC data released August 17, 2026 showed kindergarten vaccination coverage remains high nationally with only a 0.1 percent decline, though any erosion in coverage raises concern given the ongoing measles resurgence recorded domestically since early 2025.

This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  6. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. CDC Statement on Increases in Recent Animal Rabies Activity an… — CDC Newsroom
  10. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260921-02-v82 · 2026-09-21 02:01 UTC · pulse.uzylab.com

Read next